BioNTech SE (NASDAQ:BNTX) Receives $140.76 Average Price Target from Analysts

Shares of BioNTech SE (NASDAQ:BNTX) have received a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $140.76.

BNTX has been the subject of several research analyst reports. TD Cowen reduced their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. HSBC upped their target price on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Berenberg Bank assumed coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. Canaccord Genuity Group upped their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a report on Wednesday, November 27th. Finally, Bank of America lifted their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th.

BioNTech Price Performance

NASDAQ:BNTX opened at $113.95 on Friday. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a market capitalization of $27.32 billion, a price-to-earnings ratio of -54.26 and a beta of 0.22. The stock’s 50 day moving average price is $113.01 and its two-hundred day moving average price is $101.36. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the business earned $0.73 EPS. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, analysts anticipate that BioNTech will post -3.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BNTX. Planning Capital Management Corp increased its stake in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. Blue Trust Inc. lifted its position in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the last quarter. GAMMA Investing LLC boosted its stake in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares in the last quarter. Daiwa Securities Group Inc. grew its position in BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after acquiring an additional 1,562 shares during the last quarter. Finally, Caprock Group LLC acquired a new position in BioNTech during the second quarter worth about $206,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.